NCT05336812View on ClinicalTrials.gov

Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

PHASE2RecruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

September 13, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Interventions
DRUG

Acalabrutinib

Given PO

BIOLOGICAL

Obinutuzumab

Given IV

DRUG

Venetoclax

Given PO

Trial Locations (1)

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors
lead

Ohio State University Comprehensive Cancer Center

OTHER